Recent advances in pharmacological treatment of heart failure

Background Over the last years, several trials offered new evidence on heart failure (HF) treatment. Design and results For HF with reduced left ventricular ejection fraction, type 2 sodium-glucose cotransporter inhibitors, aside from sacubitril-valsartan, demonstrated extraordinary efficacy in ameliorating patients' prognosis. Some new molecules (eg vericiguat, omecamtiv mecarbil and ferric carboxymaltose) correct iron deficiency and have shown to be capable of furthering reducing the burden of HF hospitalisation. Finally, there is new evidence on the possible therapeutic approaches of HF patients with mid-range or preserved left ventricular ejection fraction. Conclusions This review aimed to revise the main novelties in the field of HF therapy and focus on how the daily clinical approach to patient treatment is changing.

Automated summary

Recent trials have shown that sodium-glucose cotransporter inhibitors and other new molecules have significant efficacy in treating heart failure, improving patient prognosis. There is also new evidence for therapeutic approaches for HF patients with mid-range or preserved left ventricular ejection fraction.